HC Wainwright Reiterates Buy Rating on Incyte Corporation
HC Wainwright maintains its positive outlook on Incyte with a $140 price target, a 23.50% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating on Incyte Corporation (INCY) with a $140 price target on June 29, 2026.
- HC Wainwright's $140 price target implies 23.50% upside from Incyte Corporation's ($INCY) current $113.36 share price.
- Shares of NasdaqGS:INCY traded near $113.75 on Monday, with a market cap of $22.7 billion and a P/E ratio of 16.07.
- Insider buying activity was noted in June, and analysts have a consensus buy rating with a target mean price of $110.70.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 29, 2026, HC Wainwright reiterated its buy rating on Incyte Corporation (NasdaqGS: INCY), setting a price target of $140. This move reflects continued confidence in Incyte's prospects by the analyst Mitchell S. Kapoor.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Incyte Corporation Stock Down 8.9%
Shares of Incyte Corporation traded near $113.75 on Monday. The company, with a market cap of approximately $22.7 billion, holds a P/E ratio of 16.07. Incyte has a 52-week low of $66.83 and a high of $115.56, with a 50-day moving average of $99.26 and a 200-day moving average of $97.33. The company's beta is 0.79, indicating relatively low volatility compared to the market.
$INCY price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Incyte reported revenue of about $5.36 billion, with a growth rate of 20.9%. The company achieved an EPS of $7.08, with a net margin of 26.7% and a return on equity of 30.8%. The next earnings report is anticipated on July 28, 2026.
Insider Buying and Selling at Incyte Corporation
Several insiders, including Otis Brawley, Edmund Harrigan, and Katherine High, purchased shares on June 8, 2026. These transactions involved a total of 11,079 shares, suggesting confidence in the company's future.
Analysts Set New Price Targets
On June 29, 2026, HC Wainwright & Co. reiterated its buy rating on Incyte with a $140 price target. UBS maintained its hold rating with a $113 target on June 26, while Truist Securities maintained a hold with a $105 target on June 22. Analysts have set a consensus buy recommendation with a target mean price of $110.70, based on 23 opinions.
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company headquartered in Wilmington, Delaware. It focuses on discovering and developing therapeutics, particularly in oncology and hematology. The company markets several treatments, including Jakafi for myelofibrosis and Iclusig for leukemia. Led by CEO William J. Meury, Incyte employs around 2,844 people and collaborates with firms like Novartis and Lilly.
Bottom Line
HC Wainwright's reiterated buy rating on Incyte Corporation with a $140 target underscores analyst confidence in the company's growth potential. Incyte's recent earnings and insider buying activity highlight its strong position in the biopharmaceutical sector. As always, remember that analyst ratings are based on past data and may not reflect current market conditions.
Get Incyte Corporation alerts
New 13F filings, insider trades, and analyst moves on $INCY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.